SC
REGN icon

Sepio Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Sepio Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.9M Sell
3,752
-149
-4% -$114K 0.16% 91
2025
Q4 		$3.01M Sell
3,901
-79
-2% -$53.6K 0.16% 87
2025
Q3 		$2.24M Buy
3,980
+23
+0.6% +$13K 0.13% 98
2025
Q2 		$2.08M Buy
3,957
+568
+17% +$317K 0.15% 101
2025
Q1 		$2.15M Buy
3,389
+842
+33% +$579K 0.17% 99
2024
Q4 		$1.81M Sell
2,547
-4
-0.2% -$3.36K 0.15% 114
2024
Q3 		$2.68M Sell
2,551
-19
-0.7% -$21.1K 0.21% 87
2024
Q2 		$2.7M Sell
2,570
-19
-0.7% -$18.4K 0.25% 83
2024
Q1 		$2.49M Sell
2,589
-113
-4% -$107K 0.21% 99
2023
Q4 		$2.37M Sell
2,702
-563
-17% -$464K 0.2% 92
2023
Q3 		$2.69M Sell
3,265
-3,718
-53% -$2.92M 0.23% 95
2023
Q2 		$5.04M Buy
6,983
+68
+1% +$52.4K 0.41% 64
2023
Q1 		$5.68M Sell
6,915
-411
-6% -$310K 0.52% 50
2022
Q4 		$5.29M Sell
7,326
-1,295
-15% -$956K 0.46% 51
2022
Q3 		$5.94M Sell
8,621
-4,800
-36% -$3.02M 0.59% 37
2022
Q2 		$7.93M Buy
13,421
+5,535
+70% +$3.6M 0.8% 23
2022
Q1 		$5.51M Sell
7,886
-839
-10% -$531K 0.48% 56
2021
Q4 		$5.51M Sell
8,725
-42
-0.5% -$25.8K 0.41% 61
2021
Q3 		$5.31M Sell
8,767
-3,566
-29% -$2.21M 0.44% 54
2021
Q2 		$6.89M Buy
12,333
+2,933
+31% +$1.49M 0.57% 36
2021
Q1 		$4.45M Sell
9,400
-55
-0.6% -$26.8K 0.41% 66
2020
Q4 		$4.57M Sell
9,455
-1,528
-14% -$825K 0.39% 67
2020
Q3 		$6.15M Sell
10,983
-427
-4% -$259K 0.67% 43
2020
Q2 		$7.12M Sell
11,410
-348
-3% -$198K 0.84% 27
2020
Q1 		$5.75M Buy
11,758
+309
+3% +$127K 0.76% 35
2019
Q4 		$4.3M Sell
11,449
-1,116
-9% -$375K 0.41% 80
2019
Q3 		$3.49M Buy
12,565
+1,880
+18% +$556K 0.36% 89
2019
Q2 		$3.34M Buy
10,685
+107
+1% +$35.6K 0.45% 69
2019
Q1 		$4.34M Sell
10,578
-1,629
-13% -$671K 0.59% 45
2018
Q4 		$4.56M Buy
+12,207
New +$4.47M 0.33% 51

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Sepio Capital's REGN Position: Q1 2026 in Review

Sepio Capital reduced its Regeneron Pharmaceuticals (REGN) stake by 3.8% in Q1 2026, selling an estimated $114K and leaving 3,752 shares worth $2.9M. The position accounts for 0.16% of the portfolio, ranked #91.

Sepio Capital first reported a position in REGN in Q4 2018 and has held it in 30 quarters since. The position peaked at $7.93M in Q2 2022. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Sepio Capital held 3,752 shares of Regeneron Pharmaceuticals worth $2.9M as of Q1 2026.
  • Sepio Capital sold 149 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $114K.
  • Regeneron Pharmaceuticals made up 0.16% of Sepio Capital's portfolio in Q1 2026, its #91 holding.
  • Sepio Capital first reported a position in Regeneron Pharmaceuticals in Q4 2018 and has held it in 30 quarters since.
  • Sepio Capital's Regeneron Pharmaceuticals position peaked at $7.93M in Q2 2022.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Sepio Capital's 13F filing for Q1 2026, filed 13 May 2026.